These shorter-term studies informed long-term clinical trials, including the “Study of Nasal Insulin Fighting Forgetfulness” (SNIFF), which evaluated 20 IU of insulin and the corresponding placebo delivered twice a day for 12 months in individuals with MCI or early AD (n = 289). Here, INS is linked to Alzheimer disease.